Compare Stryker Corporation (SYK) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Toronto-Dominion Bank — how do they compare? Stryker Corporation trades at $281.08 (market cap $106.24B), while Toronto-Dominion Bank trades at $113.45 (market cap $185.79B). The key difference: Toronto-Dominion Bank is the larger of the two by market cap, and Toronto-Dominion Bank pays the higher dividend (2.84%). Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 20 Days and Toronto-Dominion Bank for 84 Days on average.
| SYK | TD | |
|---|---|---|
Market Cap | $106.24B | $185.79B |
Volume | 2,982,001 | 3,263,867 |
Sector | Health | Financials |
52-Week High | $388.35 | $124.80 |
52-Week Low | $269.75 | $78.32 |
Typical Hold Time | 20 Days | 84 Days |
Enterprise Value | $117.70B | $559.06B |
Dividend Yield | 1.27% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker Corporation (SYK) trades at $275.40, down 1.11% amid bearish technical signals and recent negative news regarding manufacturing issues. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $3.69 versus $3.49 expected, and profitability metrics remain robust with a 14.43% net income margin. Analyst consensus remains overwhelmingly bullish with a $368.11 price target representing 33% upside potential.
Despite near-term headwinds from manufacturing disclosures and legal investigations, Stryker's solid earnings track record, strong cash flow generation, and dominant medical technology position support long-term growth prospects. Key risks include ongoing legal scrutiny and competitive pressures in the medtech sector.
TD stock trades at $113.87, down 3.65% on the day, with technical indicators showing bearish momentum. The company reported strong earnings beats in recent quarters with Q2 2026 EPS of $1.98 beating expectations of $1.74. Revenue growth continues with 2025 revenue reaching $61.28B, though cash flow volatility remains a concern with operating cash flow turning negative in 2025. The $10 billion share buyback program and $108 billion Canadian infrastructure commitment signal management confidence.
TD presents a mixed investment case with solid fundamentals offset by technical weakness. The stock offers value with a reasonable P/E of 17.36 and strong analyst support (52.94% buy ratings), but faces headwinds from cash flow volatility and declining profit margins. The current price near support levels may offer entry points for long-term investors attracted to the dividend yield and buyback program.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
